Valuation : Revance Therapeutics, Inc.

Market Cap 319M 274M 256M 235M 442M 30.46B 443M 3.03B 1.19B 15.35B 1.2B 1.17B 50.8B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 466M 437M 400M 753M 51.9B 755M 5.17B 2.02B 26.16B 2.04B 2B 86.57B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
18.94
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-80.27% 383M
-0.70%-2.08%+37.90%-2.58% 81.36B
-6.82%+6.79%+467.23%+25.08% 59.75B
+0.84%+4.44%-19.19%-35.11% 59.19B
+0.76%+3.53%+0.08%+36.18% 53.33B
+0.41%+1.84%+10.29%+170.02% 49.09B
-0.01%+3.06%+62.00%-16.65% 32.66B
-0.31%+0.41%+50.57%+97.04% 25.97B
-2.00%+9.52%+12.38%+218.34% 24.39B
+0.78%+0.47%+61.53%+123.40% 16.91B
Average -0.68%+0.14%+68.28%+53.54% 40.3B
Weighted average by Cap. -0.98%-1.01%+86.98%+46.75%

Financials

2022 2023
Net sales 133M 114M 107M 97.55M 184M 12.66B 184M 1.26B 493M 6.38B 498M 487M 21.12B 234M 201M 188M 172M 324M 22.35B 325M 2.23B 871M 11.27B 879M 860M 37.28B
Net income -356M -306M -286M -262M -494M -34.04B -495M -3.39B -1.33B -17.16B -1.34B -1.31B -56.78B -324M -278M -260M -238M -449M -30.94B -450M -3.08B -1.21B -15.6B -1.22B -1.19B -51.61B
Net Debt 77.76M 66.75M 62.49M 57.22M 108M 7.43B 108M 740M 289M 3.74B 292M 286M 12.39B 225M 193M 180M 165M 311M 21.44B 312M 2.14B 835M 10.81B 843M 825M 35.77B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock